Define the concern
Document symptoms, goals, medications and medical history instead of beginning with an online product claim.
Traducción automática para su comodidad. Para decisiones médicas,
confirme los detalles con nuestro equipo bilingüe.
Medical-Grade Peptide Therapy & Safe Sourcing
The peptide therapy education center
A plain-English, source-linked guide for men and women who want to understand what peptides are, which peptide medicines are FDA-approved, what remains investigational, and why sourcing and medical supervision matter.
- Sources reviewed July 31, 2026
- FDA status separated from evidence
- Patient-first safety
Regulatory & Clinical Update
What changed in 2025–2026
Only material updates from FDA records, registered trials and clearly labeled sponsor-reported Phase 3 results are included.
FDA-Approved
March 19, 2026
Wegovy HD 7.2 mg
FDA approved a higher-dose semaglutide injection for long-term weight reduction in certain adults. This is a product-specific option with its own labeling, not a general endorsement of higher compounded doses.
FDA Announcement Expanded Labeling August–December 2025Semaglutide label expansion
Wegovy injection gained an accelerated-approval indication for noncirrhotic MASH with F2–F3 fibrosis in adults, and FDA approved once-daily Wegovy tablets for adult chronic weight management and cardiovascular risk reduction.
FDA Prescribing Information Company Topline Data July 23, 2026Retatrutide Phase 3 readouts
Lilly reported positive TRIUMPH-1, -2 and -3 results and said it plans a U.S. submission in Q1 2027. These results are not an FDA review; retatrutide remains investigational and cannot legally be sold for human use.
Read the Evidence Update FDA Safety Update Data Through May 31, 2026Unapproved GLP-1 harms and fraud
FDA reports 990 adverse-event reports associated with compounded semaglutide and more than 730 with compounded tirzepatide, while warning about fraudulent labels, temperature failures, dosing errors and illegal research-product sales.
Review the Safety UpdateThe Evidence Map
Five labels that change what a claim actually means
These categories are related, but they are not interchangeable. The status of the exact product and proposed use matters.
| Status | What It Means | Patient Takeaway |
|---|---|---|
| FDA-Approved | Approved for a labeled use FDA reviewed the specific product’s quality, safety and effectiveness for its labeled indication. | Confirm that the proposed use matches the label. |
| Off-Label | An approved drug used differently A licensed clinician may prescribe an approved medicine for an unapproved use when medically appropriate. | Ask what evidence supports the use and what is uncertain. |
| Compounded | Prepared for a clinical need Compounded drugs are not FDA-approved; FDA does not pre-review their safety, effectiveness or quality. | Verify the prescription, pharmacy and reason compounding is needed. |
| Investigational | Still being studied Human trials may be underway, but benefits and risks are not established for routine care. Retatrutide is an example. | A clinical trial is not the same as approval or availability. |
| Research-Only | Not approved for human use Products such as BPC-157 and TB-500 are marketed despite major gaps in controlled human evidence. | Do not self-inject products labeled “research use only.” |
A Patient Decision Pathway
From symptoms to a safer decision
A peptide name should not be the starting point. Begin with the health concern, establish a diagnosis and then compare appropriate options.
Evaluate the cause
A qualified clinician determines whether examination, laboratory testing or another specialist is needed.
Compare options
Review standard care, approved medicines, off-label evidence, alternatives, expected benefit, uncertainty and cost.
Verify and monitor
Confirm the prescription and pharmacy, then establish follow-up, adverse-effect monitoring and stopping rules.
Why Supervision Matters
Peptides can affect real physiology
Peptide medicines may alter glucose, appetite, growth-hormone signaling, blood pressure, gastrointestinal function, reproductive hormones or immune responses. That makes diagnosis, medication review, baseline assessment, informed consent and follow-up clinically important.
The safest conversation is with a physician who understands the relevant field and can distinguish an approved indication from off-label use, investigational evidence and internet marketing. A prescriber should also know when a peptide is inappropriate or when symptoms require another diagnosis.
Review the Safety ChecklistSourcing Is Part of Safety
A prescription does not make every source equally trustworthy
Verify licensure
Confirm the dispensing pharmacy with the state board of pharmacy. A website, glossy label or “made in the USA” statement is not verification.
Understand 503A vs. 503B
503A pharmacies are primarily state-regulated and generally compound patient-specific prescriptions. 503B outsourcing facilities voluntarily register with FDA and are subject to CGMP requirements.
Know what certification means
LegitScript or accreditation can be an additional signal, but neither replaces state licensure, a valid prescription, FDA 503B registration where claimed, or review of inspection and recall history.
Most-Read Topics
Build your peptide baseline
Directory
FDA-approved peptide medicines
A dated, scope-defined index organized by clinical category, with the approved use and critical limitations stated clearly.
Open the Directory Evidence ReviewBPC-157, TB-500, CJC-1295 & more
What is claimed online, what human evidence exists, what the FDA says and what remains unknown.
Review Popular Compounds Patient ChecklistAvoid counterfeit and unsafe products
Questions to ask, records to verify and red flags that should stop a purchase or injection.
Use the ChecklistBefore Treatment
Ten questions to ask before saying yes
What is the exact generic and brand name of the medication?
Is this exact product FDA-approved, and is my proposed use on-label or off-label?
If compounded, why is an FDA-approved product not appropriate for my clinical need?
Which licensed pharmacy will dispense it, and can I independently verify that license?
Is the pharmacy a 503A pharmacy or FDA-registered 503B outsourcing facility?
What quality, sterility and potency documentation is available for this prescription?
What human clinical evidence supports the expected benefit for someone like me?
What are the known risks, contraindications, interactions and important unknowns?
What baseline evaluation and follow-up monitoring will I receive?
Who do I contact for an adverse reaction, and what are the stopping rules?
Regulatory & Safety FAQ
Clear answers to common questions
“Medical-grade” is not an FDA approval category. Approval belongs to a specific drug product, formulation, route, dose and indication. Ask the clinician to identify the exact product and status.
No. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before marketing. Compounding can serve legitimate patient needs, but it requires a valid prescription and careful source verification.
It means an FDA-approved drug is prescribed for a use, dose, route or patient population outside its approved labeling. Off-label does not mean automatically inappropriate, but the clinician should explain the evidence and uncertainty.
A product labeled for research use only is not approved for human use. Self-injection or treatment with an unknown-source product can expose a patient to contamination, incorrect potency, counterfeit ingredients and serious injury.
Check the active license with the pharmacy’s state board. If it claims 503B status, verify it in FDA’s registered outsourcing-facility list. Also review FDA inspection, warning-letter and recall records.
Peptide medicines can affect glucose, appetite, hormones, blood pressure, digestion and other major systems. An experienced clinician can evaluate contraindications, interactions, monitoring needs and whether another diagnosis better explains the symptoms.
Core Sources
Built from primary authorities
FDA Guidance
Compounding and FDA—questions and answers
FDA Patient Guidance
Understanding unapproved use of approved drugs
503A Compounding
Bulk drug substances used in 503A compounding
Safety Risks
Certain bulk drug substances that may present significant safety risks
Drug Safety Alert
Concerns with unapproved GLP-1 drugs used for weight loss
503B Directory
Registered 503B outsourcing facilities
Compliance Records
Compounding inspections, recalls and other actions
Current Drug Labeling
NIH DailyMed: Current FDA-approved labeling